Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3751-3761

  Ohmura Hoshino, Mari ^a,b   Yamamoto, Masafumi ^a,b,c   Yuki, Yoshikazu ^a,d   Takeda, Yoshifumi ^e   Kiyono, Hiroshi ^a,b,d,f  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e JISSEN WOMEN'S UNIVERSITY   (Japan)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adjuvant; Stx

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MUTANT VEROTOXIN 1; OVALBUMIN; UNCLASSIFIED DRUG; VEROTOXIN 1;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; ESCHERICHIA COLI; MOUSE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; NASOPHARYNX; OVALBUMIN; SHIGA-LIKE TOXIN I; UP-REGULATION;

EID: 4143140916     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.034     Document Type: Article

References (54)

1. Mestecky J., McGhee J.R. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40:1987;153-245
2. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 6(3):1988;269-277
3. Elson C.O., Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132(6):1984;2736-2741
4. Xu-Amano J., Kiyono H., Jackson R.J., et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178(4):1993;1309-1320
5. Katz J.M., Lu X., Young S.A., Galphin J.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 175(2):1997;352-363
6. Marinaro M., Staats H.F., Hiroi T., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155(10):1995;4621-4629
7. Takahashi I., Marinaro M., Kiyono H., et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173(3):1996;627-635
8. Birnabaum S., Pinto M. Local and systemic opsonic adherent. Z. Immunitatsforsch. Exp. Klin. Immunol. 151(1-2):1976;69-77
9. Roberts M., Bacon A., Rappuoli R., et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63(6):1995;2100-2108
10. Ryan M., McCarthy L., Rappuoli R., Mahon B.P., Mills K.H. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7- 1, B7-2 and CD28. Int. Immunol. 10(5):1998;651-662
11. Mrsny R.J., Daugherty A.L., Fryling C.M., FitzGerald D.J. Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Vaccine. 17(11-12):1999;1425-1433
12. Suckow M.A., Keren D.F., Brown J.E., Keusch G.T. Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice. Immunol. Cell Biol. 72(1):1994;69-74
13. Donohue-Rolfe A., Acheson D.W., Keusch G.T. Shiga toxin: purification, structure, and function. Rev. Infect. Dis. 13(Suppl. 4):1991;S293-7
14. Endo Y., Tsurigi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157: H7 and of Shiga toxin on eukaryotic ribosomes RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171:1988;45-50
15. Saxena S.K., O'Brien A.D., Ackerman E.J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264(1):1989;596-601
16. Samuel J.E., Perera L.P., Ward S., O'Brien A.D., Ginsburg V., Krivan H.C. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect. Immun. 58(3):1990;611-618
17. Stockbine N., Marques L., Newland J., Smith H., Holmes R., O'Brien A. Two toxin-converting phages from Escherichia coli O157: H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 53:1986;135-140
18. Ohmura M., Yamasaki S., Kurazono H., Kashiwagi K., Igarashi K., Takeda Y. Characterization of non-toxic mutant toxins of Vero toxin 1 that were constructed by replacing amino acids in the A subunit. Microb. Pathog. 15(3):1993;169-176
19. Ito H., Yutsudo T., Hirayama T., Takeda Y. Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 from Escherichia coli O157:H7. Microb. Pathog. 5(3):1988;189-195
20. Byun Y., Ohmura M., Fujihashi K., et al. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine. 19(15-16):2001;2061-2070
21. Larsson R., Rocksen D., Lilliehook B., Jonsson A., Bucht A. Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation. Infect. Immun. 68(12):2000;6962-6969
22. Ultrich JT, Cantrell JL, Gustafson GL, Rudbach JA, Hiernant JR. The adjuvant activity of monophsphoryl lipid A. Boca Raton, FL: CRC Press; 1991. p. 133-43.
23. Yamamoto M., Briles D.E., Yamamoto S., Ohmura M., Kiyono H., McGhee J.R. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161(8):1998;4115-4121
24. VanCott J.L., Staats H.F., Pascual D.W., et al. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156(4):1996;1504-1514
25. Yamamoto S., Takeda Y., Yamamoto M., et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185(7):1997;1203-1210
26. Swiggard W, Noncas MD, Witmer-Pack MD, Steinman RM. Enrichment of dendritic cells by plastic adherence and EA rosetting. In: Coligan JE, editor. Current Protocols in Immunology. Wiley, NY; 1991. p. 3.7.1-11.
27. Macatonia S.E., Knight S.C., Edwards A.J., Griffiths S., Fryer P. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J. Exp. Med. 166(6):1987;1654-1667
28. Austin P.R., Hovde C.J. Purification of recombinant shiga-like toxin type I B subunit. Protein Exp. Purif. 6(6):1995;771-779
29. Kojio S., Zhang H., Ohmura M., Gondaira F., Kobayashi N., Yamamoto T. Caspase-3 activation and apoptosis induction coupled with the retrograde transport of shiga toxin: inhibition by brefeldin A. FEMS Immunol. Med. Microbiol. 29(4):2000;275-281
30. Yamamoto S., Kiyono H., Yamamoto M., et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. U.S.A. 94(10):1997;5267-5272
31. Yamamoto M., Kiyono H., Yamamoto S., et al. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162(12):1999;7015-7021
32. Cong Y., Weaver C.T., Elson C.O. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159(11):1997;5301-5308
33. Jones H.P., Hodge L.M., Fujihashi K., Kiyono H., McGhee J.R., Simecka J.W. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J. Immunol. 167(8):2001;4518-4526
34. Wilson A.D., Bailey M., Williams N.A., Stokes C.R. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant. Eur. J. Immunol. 21(10):1991;2333-2339
35. Iwasaki A., Kelsall B.L. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190(2):1999;229-239
36. Gagliardi M.C., Sallusto F., Marinaro M., Langenkamp A., Lanzavecchia A M.T. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol. 30(8):2000;2394-2403
37. de Jong E.C., Vieira P.L., Kalinski P., et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J. Immunol. 168(4):2002;1704-1709
38. Ausiello C.M., Fedele G., Urbani F., Lande R., Di Carlo B., Cassone A. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J. Infect. Dis. 186(3):2002;351-360
39. Yanagita M., Hiroi T., Kitagaki N., et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J. Immunol. 162(6):1999;3559-3565
40. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56(4):1992;622-647
41. Simons K., Ikonen E. Functional rafts in cell membranes. Nature. 387(6633):1997;569-572
42. Isaka M., Yasuda Y., Kozuka S., et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 18(7-8):1999;743-751
43. Tochikubo K., Isaka M., Yasuda Y., et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine. 16(2-3):1998;150-155
44. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22(9):1992;2277-2281
45. Elson C.O., Holland S.P., Dertzbaugh M.T., Cuff C.F., Anderson A.O. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J. Immunol. 154(3):1995;1032-1040
46. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65(7):1997;2821-2828
47. Douce G., Turcotte C., Cropley I., et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. U.S.A. 92(5):1995;1644-1648
48. Di Tommaso A., Saletti G., Pizza M., et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64(3):1996;974-979
49. Giuliani M.M., Del Giudice G., Giannelli V., et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP- ribosyltransferase activity. J. Exp. Med. 187(7):1998;1123-1132
50. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63(5):1995;1617-1623
51. Paton J.C., Paton A.W. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11(3):1998;450-479
52. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20(11):1999;493-500
53. Kuo C.T., Leiden J.M. Transcriptional regulation of T lymphocyte development and function. Annu. Rev. Immunol. 17:1999;149-187
54. Madrenas J. A SLAT in the Th2 signalosome. Immunity. 18(4):2003;459-461